Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sofusa Holdings LLC has 3 pending office actions in the Medical Devices & Mechanical Engineering technology area. These actions involve 3 distinct examiners. The workload is distributed across 2 distinct art units, indicating some level of organizational variety in the prosecution process. This spread suggests that the company's technology may bridge different technical classifications within the patent office's structure, requiring engagement with multiple administrative groups.
The busiest examiner for the portfolio is STEPHENS, AMELIA CAROLE, who is responsible for 1 pending office action. Since there are 3 pending actions and 3 distinct examiners, each examiner is currently managing exactly 1 action. This parity across the examiner pool suggests a broad spread of the company's active legal matters. Practitioners should be prepared to navigate the differing expectations of multiple examiners across these two art units in the medical device sector.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, QUYNH-NHU HOANG | 1 | 68.5% | +27.4% |
| STEPHENS, AMELIA CAROLE | 1 | 85.7% | +33.3% |
| PRICE, NATHAN R | 1 | 53.4% | +38.9% |
| AHMED, TASNIM M | 1 | 81.1% | +5.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568260 | METHOD OF TREATING CANCER BY ADMINISTRATION OF AN ANTI-PD-1 OR ANTI-PD-L1 THERAPEUTIC AGENT VIA A LYMPHATIC MICRONEEDLE DELIVERY DEVICE | STEPHENS, AMELIA CAROLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17784994 | FLUID DELIVERY APPARATUS WITH MICRONEEDLES | PRICE, NATHAN R | 27d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17784994 | FLUID DELIVERY APPARATUS WITH MICRONEEDLES | PRICE, NATHAN R | 27d |
| 18622067 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | VU, QUYNH-NHU HOANG | — |
| 18568260 | METHOD OF TREATING CANCER BY ADMINISTRATION OF AN ANTI-PD-1 OR ANTI-PD-L1 THERAPEUTIC AGENT VIA A LYMPHATIC MICRONEEDLE DELIVERY DEVICE | STEPHENS, AMELIA CAROLE | — |
| Art Unit | Apps |
|---|---|
| 3783 | 2 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18622067 | METHODS FOR BETTER DELIVERY OF ACTIVE AGENTS TO TUMORS | VU, QUYNH-NHU HOANG | — | §103 | Final Rejection | — | Pending | Mar 29, 2024 |
| 18568260 | METHOD OF TREATING CANCER BY ADMINISTRATION OF AN ANTI-PD-1 OR ANTI-PD-L1 THERAPEUTIC AGENT VIA A LYMPHATIC MICRONEEDLE DELIVERY DEVICE | STEPHENS, AMELIA CAROLE | 1645 | §112 | Final Rejection | — | Pending | Dec 07, 2023 |
| 17784994 | FLUID DELIVERY APPARATUS WITH MICRONEEDLES | PRICE, NATHAN R | 3783 | §103§112 | Final Rejection | 27d | Pending | Jun 13, 2022 |
| 17464402 | MEDICAL DEVICES FOR DELIVERY OF siRNA | AHMED, TASNIM M | 3783 | Other | Non-Final OA | 367d overdue | Pending | Sep 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial